Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EBIT (2016 - 2025)

Historic EBIT for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $11.8 million.

  • Integra Lifesciences Holdings' EBIT rose 24430.67% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$480.8 million, marking a year-over-year decrease of 176753.26%. This contributed to the annual value of $28.4 million for FY2024, which is 7452.52% down from last year.
  • According to the latest figures from Q3 2025, Integra Lifesciences Holdings' EBIT is $11.8 million, which was up 24430.67% from -$512.7 million recorded in Q2 2025.
  • Integra Lifesciences Holdings' 5-year EBIT high stood at $67.8 million for Q4 2022, and its period low was -$512.7 million during Q2 2025.
  • In the last 5 years, Integra Lifesciences Holdings' EBIT had a median value of $35.6 million in 2024 and averaged $3.1 million.
  • As far as peak fluctuations go, Integra Lifesciences Holdings' EBIT surged by 26828.12% in 2021, and later tumbled by 1682552.0% in 2025.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' EBIT stood at $58.2 million in 2021, then grew by 16.52% to $67.8 million in 2022, then plummeted by 46.86% to $36.0 million in 2023, then decreased by 1.17% to $35.6 million in 2024, then plummeted by 66.99% to $11.8 million in 2025.
  • Its EBIT was $11.8 million in Q3 2025, compared to -$512.7 million in Q2 2025 and -$15.5 million in Q1 2025.